Work Here?
Overview
Company Does Not Provide H1B Sponsorship
Signos provides a wearable device paired with an app to help people manage their metabolism and health. The wearable continuously tracks blood sugar and shows trends, while the app uses that data to offer personalized guidance based on how a user responds to food. The product works by collecting real-time glucose data, analyzing it with AI and a large pool of data, and delivering features like meal- and fasting-related tips, predicted glucose responses for meals, exercise suggestions, and alerts when glucose spikes occur. Signos differentiates itself through metabolism-based, personalized recommendations tied to continuous glucose monitoring, plus in-app nutritionist support and predictive meal insights, all delivered through a subscription. Its goal is to help users lose weight, manage blood sugar, and improve overall health by making informed dietary and lifestyle choices.
About Signos
Industries
Data & Analytics
Hardware
Consumer Software
Healthcare
Company Size
51-200
Company Stage
Series B
Total Funding
$33M
Headquarters
Burlingame, California
Founded
2019
Get referred to Signos
See people who can refer or advise you
Simplify's Take
What believers are saying
- 2026 funding from GV, Dexcom, and Blue Cross Blue Shield signals validation.
- Weight-loss demand rose with GLP-1 adoption, and Signos targets adjacent users.
- Dexcom site placement should lower acquisition costs and expand consumer reach quickly.
What critics are saying
- Insurance still does not cover Signos; customers pay $129-$139 monthly subscriptions.
- The 2025 clearance remains device-led; published trial data are still limited.
- Dexcom can commoditize Signos by bundling similar weight-management software into Stelo.
What makes Signos unique
- 2025 FDA cleared Signos' OTC glucose-monitoring system for weight management.
- Signos pairs Dexcom Stelo sensors with AI coaching on meals, movement, sleep, stress.
- 2026 Dexcom distribution on Stelo.com gives Signos a built-in channel.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$33M
Below
Industry Average
Funded Over
2 Rounds
Industry standards
Benefits
Health Insurance
Dental Insurance
Vision Insurance
401(k) Retirement Plan
Unlimited Paid Time Off
Remote Work Options
Growth & Insights and Company News
6 month growth
↑ 2%1 year growth
↑ 6%2 year growth
↑ 5%PALO ALTO, Calif., Aug. 20, 2025 /PRNewswire/ - Signos, a purpose-driven metabolic health platform committed to transforming lives through personalized, real-time insights, today announced the launch of Signos Glucose Monitoring System, the first ever FDA-cleared, over-the-counter glucose monitoring system for weight management.
Signos, a comprehensive metabolic health platform that includes a proprietary AI-engine with a continuous glucose monitor (CGM) to provide real-time d
Signos also integrates with smart watches, smart scales and Apple Health data to track metrics.
Wearable startup Signos said Tuesday that it closed a $20 million funding round led by Cheyenne Ventures and GV, formerly Google Ventures.
In lieu of FDA approval, Signos has launched a five-year, 20,000-person study to prove that its app can help people lose weight.
Signos is Hiring for 1 Jobs on Simplify!
Find jobs on Simplify and start your career today
About Signos
Industries
Data & Analytics
Hardware
Consumer Software
Healthcare
Company Size
51-200
Company Stage
Series B
Total Funding
$33M
Headquarters
Burlingame, California
Founded
2019
Signos is Hiring for 1 Jobs on Simplify!
Find jobs on Simplify and start your career today